Matthew P Goetz, James M Rae, Vera J Suman, Stephanie L Safgren, Matthew M Ames, Daniel W Visscher, Carol Reynolds, Fergus J Couch, Wilma L Lingle, David A Flockhart, Zeruesenay Desta, Edith A Perez, James N Ingle. J Clin Oncol 2005
Times Cited: 577
Times Cited: 577
Times Cited
Times Co-cited
Similarity
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell'orto, Maria Olivia Biasi, Beat Thürlimann, Maria B Lyng,[...]. J Natl Cancer Inst 2012
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell'orto, Maria Olivia Biasi, Beat Thürlimann, Maria B Lyng,[...]. J Natl Cancer Inst 2012
37
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Werner Schroth, Matthew P Goetz, Ute Hamann, Peter A Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J Suman, Matthew M Ames,[...]. JAMA 2009
Werner Schroth, Matthew P Goetz, Ute Hamann, Peter A Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J Suman, Matthew M Ames,[...]. JAMA 2009
34
Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
L Madlensky, L Natarajan, S Tchu, M Pu, J Mortimer, S W Flatt, D M Nikoloff, G Hillman, M R Fontecha, H J Lawrence,[...]. Clin Pharmacol Ther 2011
L Madlensky, L Natarajan, S Tchu, M Pu, J Mortimer, S W Flatt, D M Nikoloff, G Hillman, M R Fontecha, H J Lawrence,[...]. Clin Pharmacol Ther 2011
33
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Werner Schroth, Lydia Antoniadou, Peter Fritz, Matthias Schwab, Thomas Muerdter, Ulrich M Zanger, Wolfgang Simon, Michel Eichelbaum, Hiltrud Brauch. J Clin Oncol 2007
Werner Schroth, Lydia Antoniadou, Peter Fritz, Matthias Schwab, Thomas Muerdter, Ulrich M Zanger, Wolfgang Simon, Michel Eichelbaum, Hiltrud Brauch. J Clin Oncol 2007
28
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Yan Jin, Zeruesenay Desta, Vered Stearns, Bryan Ward, Herbert Ho, Kyung-Hoon Lee, Todd Skaar, Anna Maria Storniolo, Lang Li, Adjei Araba,[...]. J Natl Cancer Inst 2005
Yan Jin, Zeruesenay Desta, Vered Stearns, Bryan Ward, Herbert Ho, Kyung-Hoon Lee, Todd Skaar, Anna Maria Storniolo, Lang Li, Adjei Araba,[...]. J Natl Cancer Inst 2005
28
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
Zeruesenay Desta, Bryan A Ward, Nadia V Soukhova, David A Flockhart. J Pharmacol Exp Ther 2004
Zeruesenay Desta, Bryan A Ward, Nadia V Soukhova, David A Flockhart. J Pharmacol Exp Ther 2004
27
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.
P Saladores, T Mürdter, D Eccles, B Chowbay, N K Zgheib, S Winter, B Ganchev, B Eccles, S Gerty, A Tfayli,[...]. Pharmacogenomics J 2015
P Saladores, T Mürdter, D Eccles, B Chowbay, N K Zgheib, S Winter, B Ganchev, B Eccles, S Gerty, A Tfayli,[...]. Pharmacogenomics J 2015
27
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
James M Rae, Suzy Drury, Daniel F Hayes, Vered Stearns, Jacklyn N Thibert, Ben P Haynes, Janine Salter, Ivana Sestak, Jack Cuzick, Mitch Dowsett. J Natl Cancer Inst 2012
James M Rae, Suzy Drury, Daniel F Hayes, Vered Stearns, Jacklyn N Thibert, Ben P Haynes, Janine Salter, Ivana Sestak, Jack Cuzick, Mitch Dowsett. J Natl Cancer Inst 2012
26
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Vered Stearns, Michael D Johnson, James M Rae, Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F Hayes, Zeruesenay Desta, David A Flockhart. J Natl Cancer Inst 2003
Vered Stearns, Michael D Johnson, James M Rae, Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F Hayes, Zeruesenay Desta, David A Flockhart. J Natl Cancer Inst 2003
24
23
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
M A Province, M P Goetz, H Brauch, D A Flockhart, J M Hebert, R Whaley, V J Suman, W Schroth, S Winter, H Zembutsu,[...]. Clin Pharmacol Ther 2014
M A Province, M P Goetz, H Brauch, D A Flockhart, J M Hebert, R Whaley, V J Suman, W Schroth, S Winter, H Zembutsu,[...]. Clin Pharmacol Ther 2014
23
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
T E Mürdter, W Schroth, L Bacchus-Gerybadze, S Winter, G Heinkele, W Simon, P A Fasching, T Fehm, M Eichelbaum, M Schwab,[...]. Clin Pharmacol Ther 2011
T E Mürdter, W Schroth, L Bacchus-Gerybadze, S Winter, G Heinkele, W Simon, P A Fasching, T Fehm, M Eichelbaum, M Schwab,[...]. Clin Pharmacol Ther 2011
22
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Silvana Borges, Zeruesenay Desta, Lang Li, Todd C Skaar, Bryan A Ward, Anne Nguyen, Yan Jin, Anna Maria Storniolo, D Michele Nikoloff, Lin Wu,[...]. Clin Pharmacol Ther 2006
Silvana Borges, Zeruesenay Desta, Lang Li, Todd C Skaar, Bryan A Ward, Anne Nguyen, Yan Jin, Anna Maria Storniolo, D Michele Nikoloff, Lin Wu,[...]. Clin Pharmacol Ther 2006
21
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
20
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Matthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W Fraser Symmans, Howard L McLeod, Mark J Ratain, Hitoshi Zembutsu,[...]. Clin Pharmacol Ther 2018
Matthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W Fraser Symmans, Howard L McLeod, Mark J Ratain, Hitoshi Zembutsu,[...]. Clin Pharmacol Ther 2018
19
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kazuma Kiyotani, Taisei Mushiroda, Chiyo K Imamura, Naoya Hosono, Tatsuhiko Tsunoda, Michiaki Kubo, Yusuke Tanigawara, David A Flockhart, Zeruesenay Desta, Todd C Skaar,[...]. J Clin Oncol 2010
Kazuma Kiyotani, Taisei Mushiroda, Chiyo K Imamura, Naoya Hosono, Tatsuhiko Tsunoda, Michiaki Kubo, Yusuke Tanigawara, David A Flockhart, Zeruesenay Desta, Todd C Skaar,[...]. J Clin Oncol 2010
17
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill,[...]. Lancet 2013
Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill,[...]. Lancet 2013
17
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Michael D Johnson, Hong Zuo, Kyung-Hoon Lee, Joseph P Trebley, James Michael Rae, Ross V Weatherman, Zeruesanay Desta, David A Flockhart, Todd C Skaar. Breast Cancer Res Treat 2004
Michael D Johnson, Hong Zuo, Kyung-Hoon Lee, Joseph P Trebley, James Michael Rae, Ross V Weatherman, Zeruesanay Desta, David A Flockhart, Todd C Skaar. Breast Cancer Res Treat 2004
17
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Anabel Sanchez-Spitman, Vincent Dezentjé, Jesse Swen, Dirk Jan A R Moes, Stefan Böhringer, Erdogan Batman, Edith van Druten, Carolien Smorenburg, Aart van Bochove, Anneke Zeillemaker,[...]. J Clin Oncol 2019
Anabel Sanchez-Spitman, Vincent Dezentjé, Jesse Swen, Dirk Jan A R Moes, Stefan Böhringer, Erdogan Batman, Edith van Druten, Carolien Smorenburg, Aart van Bochove, Anneke Zeillemaker,[...]. J Clin Oncol 2019
29
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Matthew P Goetz, Vera J Suman, Tanya L Hoskin, Michael Gnant, Martin Filipits, Stephanie L Safgren, Mary Kuffel, Raimund Jakesz, Margaretha Rudas, Richard Greil,[...]. Clin Cancer Res 2013
Matthew P Goetz, Vera J Suman, Tanya L Hoskin, Michael Gnant, Martin Filipits, Stephanie L Safgren, Mary Kuffel, Raimund Jakesz, Margaretha Rudas, Richard Greil,[...]. Clin Cancer Res 2013
19
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.
L DiAnne Bradford. Pharmacogenomics 2002
L DiAnne Bradford. Pharmacogenomics 2002
16
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Pia Wegman, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld, Sten Wingren. Breast Cancer Res 2007
Pia Wegman, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld, Sten Wingren. Breast Cancer Res 2007
15
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Young Chai Lim, Zeruesenay Desta, David A Flockhart, Todd C Skaar. Cancer Chemother Pharmacol 2005
Young Chai Lim, Zeruesenay Desta, David A Flockhart, Todd C Skaar. Cancer Chemother Pharmacol 2005
14
The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
L K Teh, N I Mohamed, M Z Salleh, M Rohaizak, N S Shahrun, J J Saladina, J K S Shia, H Roslan, S Sood, T S Rajoo,[...]. AAPS J 2012
L K Teh, N I Mohamed, M Z Salleh, M Rohaizak, N S Shahrun, J J Saladina, J K S Shia, H Roslan, S Sood, T S Rajoo,[...]. AAPS J 2012
27
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Susan A Nowell, Jiyoung Ahn, James M Rae, Joshua O Scheys, Andrew Trovato, Carol Sweeney, Stewart L MacLeod, Fred F Kadlubar, Christine B Ambrosone. Breast Cancer Res Treat 2005
Susan A Nowell, Jiyoung Ahn, James M Rae, Joshua O Scheys, Andrew Trovato, Carol Sweeney, Stewart L MacLeod, Fred F Kadlubar, Christine B Ambrosone. Breast Cancer Res Treat 2005
14
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.
A Gaedigk, S D Simon, R E Pearce, L D Bradford, M J Kennedy, J S Leeder. Clin Pharmacol Ther 2008
A Gaedigk, S D Simon, R E Pearce, L D Bradford, M J Kennedy, J S Leeder. Clin Pharmacol Ther 2008
14
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
V O Dezentjé, F L Opdam, H Gelderblom, J Hartigh den, T Van der Straaten, R Vree, E Maartense, C H Smorenburg, H Putter, A S Dieudonné,[...]. Breast Cancer Res Treat 2015
V O Dezentjé, F L Opdam, H Gelderblom, J Hartigh den, T Van der Straaten, R Vree, E Maartense, C H Smorenburg, H Putter, A S Dieudonné,[...]. Breast Cancer Res Treat 2015
33
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Y Xu, Y Sun, L Yao, L Shi, Y Wu, T Ouyang, J Li, T Wang, Z Fan, T Fan,[...]. Ann Oncol 2008
Y Xu, Y Sun, L Yao, L Shi, Y Wu, T Ouyang, J Li, T Wang, Z Fan, T Fan,[...]. Ann Oncol 2008
13
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Joanne S L Lim, Xiang A Chen, Onkar Singh, Yoon S Yap, Raymond C H Ng, Nan S Wong, Mabel Wong, Edmund J D Lee, Balram Chowbay. Br J Clin Pharmacol 2011
Joanne S L Lim, Xiang A Chen, Onkar Singh, Yoon S Yap, Raymond C H Ng, Nan S Wong, Mabel Wong, Edmund J D Lee, Balram Chowbay. Br J Clin Pharmacol 2011
15
Clinical and biomarker predictors of side effects from tamoxifen.
Wendy Lorizio, Alan H B Wu, Mary S Beattie, Hope Rugo, Simone Tchu, Karla Kerlikowske, Elad Ziv. Breast Cancer Res Treat 2012
Wendy Lorizio, Alan H B Wu, Mary S Beattie, Hope Rugo, Simone Tchu, Karla Kerlikowske, Elad Ziv. Breast Cancer Res Treat 2012
17
Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Lisette Binkhorst, Ron H J Mathijssen, Agnes Jager, Teun van Gelder. Cancer Treat Rev 2015
Lisette Binkhorst, Ron H J Mathijssen, Agnes Jager, Teun van Gelder. Cancer Treat Rev 2015
19
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Peter Fox, Rosemary L Balleine, Clara Lee, Bo Gao, Bavanthi Balakrishnar, Alexander M Menzies, Shang Heng Yeap, Sayed Sahanawaz Ali, Val Gebski, Pamela Provan,[...]. Clin Cancer Res 2016
Peter Fox, Rosemary L Balleine, Clara Lee, Bo Gao, Bavanthi Balakrishnar, Alexander M Menzies, Shang Heng Yeap, Sayed Sahanawaz Ali, Val Gebski, Pamela Provan,[...]. Clin Cancer Res 2016
23
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
William J Irvin, Christine M Walko, Karen E Weck, Joseph G Ibrahim, Wing K Chiu, E Claire Dees, Susan G Moore, Oludamilola A Olajide, Mark L Graham, Sean T Canale,[...]. J Clin Oncol 2011
William J Irvin, Christine M Walko, Karen E Weck, Joseph G Ibrahim, Wing K Chiu, E Claire Dees, Susan G Moore, Oludamilola A Olajide, Mark L Graham, Sean T Canale,[...]. J Clin Oncol 2011
11
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
J Gjerde, M Hauglid, H Breilid, S Lundgren, J E Varhaug, E R Kisanga, G Mellgren, V M Steen, E A Lien. Ann Oncol 2008
J Gjerde, M Hauglid, H Breilid, S Lundgren, J E Varhaug, E R Kisanga, G Mellgren, V M Steen, E A Lien. Ann Oncol 2008
11
Pharmacogenomics of tamoxifen therapy.
Hiltrud Brauch, Thomas E Mürdter, Michel Eichelbaum, Matthias Schwab. Clin Chem 2009
Hiltrud Brauch, Thomas E Mürdter, Michel Eichelbaum, Matthias Schwab. Clin Chem 2009
11
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.
Werner Schroth, Stefan Winter, Thomas Mürdter, Elke Schaeffeler, Diana Eccles, Bryony Eccles, Balram Chowbay, Chiea C Khor, Arafat Tfayli, Nathalie K Zgheib,[...]. Front Pharmacol 2017
Werner Schroth, Stefan Winter, Thomas Mürdter, Elke Schaeffeler, Diana Eccles, Bryony Eccles, Balram Chowbay, Chiea C Khor, Arafat Tfayli, Nathalie K Zgheib,[...]. Front Pharmacol 2017
30
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
Matthew P Goetz, James X Sun, Vera J Suman, Grace O Silva, Charles M Perou, Yusuke Nakamura, Nancy J Cox, Philip J Stephens, Vincent A Miller, Jeffrey S Ross,[...]. J Natl Cancer Inst 2014
Matthew P Goetz, James X Sun, Vera J Suman, Grace O Silva, Charles M Perou, Yusuke Nakamura, Nancy J Cox, Philip J Stephens, Vincent A Miller, Jeffrey S Ross,[...]. J Natl Cancer Inst 2014
25
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Pia Wegman, Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist, Sten Wingren. Breast Cancer Res 2005
Pia Wegman, Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist, Sten Wingren. Breast Cancer Res 2005
10
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
Alastair M Thompson, Andrea Johnson, Philip Quinlan, Grantland Hillman, Marcel Fontecha, Susan E Bray, Colin A Purdie, Lee B Jordan, Roberta Ferraldeschi, Ayshe Latif,[...]. Breast Cancer Res Treat 2011
Alastair M Thompson, Andrea Johnson, Philip Quinlan, Grantland Hillman, Marcel Fontecha, Susan E Bray, Colin A Purdie, Lee B Jordan, Roberta Ferraldeschi, Ayshe Latif,[...]. Breast Cancer Res Treat 2011
13
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
V C Jordan, M M Collins, L Rowsby, G Prestwich. J Endocrinol 1977
V C Jordan, M M Collins, L Rowsby, G Prestwich. J Endocrinol 1977
10
Genotype-guided tamoxifen therapy: time to pause for reflection?
Timothy L Lash, Ernst A Lien, Henrik Toft Sørensen, Stephen Hamilton-Dutoit. Lancet Oncol 2009
Timothy L Lash, Ernst A Lien, Henrik Toft Sørensen, Stephen Hamilton-Dutoit. Lancet Oncol 2009
11
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Vincent O Dezentjé, Hans Gelderblom, Ron H N Van Schaik, Judith M Vletter-Bogaartz, Tahar Van der Straaten, Judith A M Wessels, Elma Meershoek-Klein Kranenbarg, Els M Berns, Caroline Seynaeve, Hein Putter,[...]. Breast Cancer Res Treat 2014
Vincent O Dezentjé, Hans Gelderblom, Ron H N Van Schaik, Judith M Vletter-Bogaartz, Tahar Van der Straaten, Judith A M Wessels, Elma Meershoek-Klein Kranenbarg, Els M Berns, Caroline Seynaeve, Hein Putter,[...]. Breast Cancer Res Treat 2014
90
Prediction of CYP2D6 phenotype from genotype across world populations.
Andrea Gaedigk, Katrin Sangkuhl, Michelle Whirl-Carrillo, Teri Klein, J Steven Leeder. Genet Med 2017
Andrea Gaedigk, Katrin Sangkuhl, Michelle Whirl-Carrillo, Teri Klein, J Steven Leeder. Genet Med 2017
10
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Jean E Abraham, Mel J Maranian, Kristy E Driver, Radka Platte, Bolot Kalmyrzaev, Caroline Baynes, Craig Luccarini, Mitul Shah, Susan Ingle, David Greenberg,[...]. Breast Cancer Res 2010
Jean E Abraham, Mel J Maranian, Kristy E Driver, Radka Platte, Bolot Kalmyrzaev, Caroline Baynes, Craig Luccarini, Mitul Shah, Susan Ingle, David Greenberg,[...]. Breast Cancer Res 2010
12
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Solai Elango Damodaran, Suresh Chandra Pradhan, Gurusamy Umamaheswaran, Dharanipragada Kadambari, K Sathyanarayana Reddy, Chandrasekaran Adithan. Cancer Chemother Pharmacol 2012
Solai Elango Damodaran, Suresh Chandra Pradhan, Gurusamy Umamaheswaran, Dharanipragada Kadambari, K Sathyanarayana Reddy, Chandrasekaran Adithan. Cancer Chemother Pharmacol 2012
25
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.
T Ramón y Cajal, A Altés, L Paré, E del Rio, C Alonso, A Barnadas, M Baiget. Breast Cancer Res Treat 2010
T Ramón y Cajal, A Altés, L Paré, E del Rio, C Alonso, A Barnadas, M Baiget. Breast Cancer Res Treat 2010
14
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.
Deirdre P Cronin-Fenton, Per Damkier, Timothy L Lash. Future Oncol 2014
Deirdre P Cronin-Fenton, Per Damkier, Timothy L Lash. Future Oncol 2014
16
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
V O Dezentjé, R H N van Schaik, J M Vletter-Bogaartz, T van der Straaten, J A M Wessels, E M-K Kranenbarg, E M Berns, C Seynaeve, H Putter, C J H van de Velde,[...]. Breast Cancer Res Treat 2013
V O Dezentjé, R H N van Schaik, J M Vletter-Bogaartz, T van der Straaten, J A M Wessels, E M-K Kranenbarg, E M Berns, C Seynaeve, H Putter, C J H van de Velde,[...]. Breast Cancer Res Treat 2013
25
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
N Lynn Henry, James M Rae, Lang Li, Faouzi Azzouz, Todd C Skaar, Zereunesay Desta, Matthew J Sikora, Santosh Philips, Anne T Nguyen, Anna Maria Storniolo,[...]. Breast Cancer Res Treat 2009
N Lynn Henry, James M Rae, Lang Li, Faouzi Azzouz, Todd C Skaar, Zereunesay Desta, Matthew J Sikora, Santosh Philips, Anne T Nguyen, Anna Maria Storniolo,[...]. Breast Cancer Res Treat 2009
18
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Thomas P Ahern, Daniel L Hertz, Per Damkier, Bent Ejlertsen, Stephen J Hamilton-Dutoit, James M Rae, Meredith M Regan, Alastair M Thompson, Timothy L Lash, Deirdre P Cronin-Fenton. Am J Epidemiol 2017
Thomas P Ahern, Daniel L Hertz, Per Damkier, Bent Ejlertsen, Stephen J Hamilton-Dutoit, James M Rae, Meredith M Regan, Alastair M Thompson, Timothy L Lash, Deirdre P Cronin-Fenton. Am J Epidemiol 2017
32
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.